NCT06427395进行中（未招募）3 期
A Multicenter, Open-Label, Extension Clinical Trial to Evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (PBC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 102
- 试验地点
- 28
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
研究概览
简要总结
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
详细描述
A Multicenter, Open-Label, Extension Clinical trial to evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis (PBC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must provide written informed consent and agree to comply with the trial protocol
- •Participated and completed SARO.21.001, the double-blind treatment phase study
排除标准
- •Consumption of 2 standard drinks per day if male and 1 standard drink per day if female for 3 consecutive months (12 consecutive weeks) throughout double-blind phase till screening.
- •Participants with MELD 3.0 score of 15 or greater
- •History or presence of other concomitant liver diseases at screening:
- •Chronic hepatitis B or C virus (HBV, HCV) infection
- •Primary sclerosing cholangitis (PSC)
- •Alcoholic liver disease
- •Autoimmune hepatitis (AIH)-PBC overlap syndrome
- •Hemochromatosis
- •Non-alcoholic steatohepatitis (NASH) on historical biopsy
- •Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, uncontrolled ascites, encephalopathy, history of variceal bleeding or history of hepatorenal syndrome at screening.
- •Use of Thiazolidinediones or Fibrates (within 12 weeks prior to screening)
- •Use of other PPAR agonists (i.e., Elafibranor, Seladelpar), Obeticholic acid (OCA), methotrexate, budesonide and other systemic corticosteroids (Prednisone dose more than 10 mg); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin) (within 12 weeks prior to screening)
- •History of bowel surgery (gastrointestinal [bariatric] surgery in the preceding 1 year or undergoing evaluation for gastrointestinal surgery (bariatric surgery for obesity, extensive small-bowel resection) or orthotopic liver transplant (OLT) or listed for OLT
- •Unstable cardiovascular disease, including:
- •Unstable angina, (i.e., new or worsening symptoms of coronary heart disease in the 12 weeks before screening and throughout the screening period), acute coronary syndrome in the 24 weeks before screening and throughout the screening period, acute myocardial infarction in the 12 weeks before screening and throughout the screening period or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, in the 24 weeks before screening and throughout the screening period
- •History/current unstable cardiac dysrhythmias
- •Uncontrolled hypertension at screening
- •Stroke or transient ischemic attack in the 24 weeks before screening
- •History of intracranial hemorrhage, arteriovenous malformation, bleeding disorder, and coagulation disorders
- •An uncontrolled thyroid disorder
- •Uncontrolled hyperthyroidism: defined as any history of hyperthyroidism that has either not been treated with either radioactive iodine and/or surgery or that has been treated with radioactive iodine and/or surgery, but has required ongoing continuous or intermittent use of thyroid hormone synthesis inhibitors (i.e., methimazole or propylthiouracil) in the 24 weeks before screening
- •Uncontrolled hypothyroidism: defined as initiation of thyroid hormone replacement therapy or dose adjustment of replacement therapy in the 12 weeks before screening
- •History of myopathies or evidence of active muscle disease demonstrated by CPK ≥ 5 × ULN at screening
- •Any of the following laboratory values:
- •Total bilirubin > 3 x ULN
- •Platelets < 50 × 103/mL
- •Albumin < 2.8 g/dL
- •eGFR < 45 mL/min/1.73 m2
- •ALT or AST > 250 U/L
- •ALP > 10 × ULN
- •Participation in another interventional clinical study and receipt of any other investigational medication or medical device within 30 days or within 5 half-lives, whatever is longer, prior to screening
- •History of malignancy in the past 5 years and/or active neoplasm which may diminish life expectancy (except resolved superficial non-melanoma skin cancer, carcinomas in situ or other stable, relatively benign conditions if appropriately treated prior to screening)
- •Known allergy, sensitivity or intolerance to the study medication or formulation ingredients
- •Pregnancy-related exclusions, including:
- •Pregnant/lactating female (including positive pregnancy test at screening)
- •Participants agree to avoid pregnancy either by true abstinence or the use of an acceptable effective contraceptive measures for the duration of the study and for at least 1 month after the end of the study medication. Refer Appendix 9 Contraceptive Guidance.
- •History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, HIV, coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption)
- •Cirrhosis with Child-Pugh-Turcotte (CPT) class B or C having score of 7 or above at screening (Refer Appendix 11
研究组 & 干预措施
Saroglitazar Magnesium 1 mg
Experimental
Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 months).
干预措施: Saroglitazar Magnesium 1 mg (Drug)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
时间窗: From baseline to 24 Months/EOT
次要结局
- Proportion of participants achieving biochemical response based on the composite endpoints of ALP and total bilirubin(From baseline to Months 12 and 24/EOT)
- Proportion of participants with biochemical response based on the composite endpoints of ALP and total bilirubin(From baseline to Months 12 and 24/EOT)
- Time to first occurrence of Liver transplant or placement on a liver transplant list(From baseline to 24 Months/EOT)
- Time to occurrence of the clinical outcome events in study participants with PBC(From baseline to 24 Months/EOT)
- Time to the occurrence of Death(From baseline to 24 Months/EOT)
- Time to occurrence of the clinical outcome events based on Model for End Stage Liver Disease 3.0 score(From baseline to 24 Months/EOT)
- Effect on liver stiffness measurement (LSM) assessed by Liver elastography/FibroScan(From baseline to Months 12 and 24/EOT)
- Effect on liver enzyme parameters(From baseline to Months 12 and 24/EOT)
- Effect on lipid parameters(From baseline to Months 12 and 24/EOT)
- Effect on disease-related symptoms(From baseline to Months 12 and 24/EOT)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
2 期
Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisPrimary Biliary CholangitisNCT05133336Zydus Therapeutics Inc.196
终止
3 期
Open-Label Phase 3 Long-Term Safety Study of MigalastatFabry DiseaseNCT01458119Amicus Therapeutics85
撤回
2 期
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary CirrhosisPrimary Biliary CirrhosisNCT02321306Mirum Pharmaceuticals, Inc.
Unknown
2 期
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile NeutropeniaFebrile NeutropeniaNCT03449693Universidad Nacional Autonoma de Mexico214
终止
2 期
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 StudyFabry DiseaseNCT00526071Amicus Therapeutics23